과제정보
본 연구는 과학기술정보통신부/한국연구재단 이공분야기초연구사업의 지원으로 수행되었으며(과제번호: 2022R1F1A1075439) 이에 감사드립니다.
참고문헌
- Tu KN, Lie JD, Wan CKV , et al. Osteoporosis: A review of treatment options. Pharmacy and Therapeutics 2018;43(2):92-104. https://doi.org/10.1111/jcpt.12616
- Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 2020;26(Suppl 1):1-46.
- Jeon Y, Kim I-J. Pharmacological treatment of osteoporosis: 2022 update. J Korean Med Assoc 2022;65(4):241-8. https://doi.org/10.5124/jkma.2022.65.4.241
- Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a rankl-dependent pathway. PLoS One 2011;6(10):e25900.
- Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis 2014;6(2):48-57. https://doi.org/10.1177/1759720X13510479
- Kobza AO, Papaioannou A, Lau AN, et al. Romosozumab in the treatment of osteoporosis. Immunotherapy 2020;12(13):965-81. https://doi.org/10.2217/imt-2020-0158
- Sanabria-de la Torre R, Gonzalez-Salvatierra S, Garcia-Fontana C, et al. Exploring the role of sclerostin as a biomarker of cardiovascular disease and mortality: A scoping review. Int J Environ Res Public Health 2022;19(23):15981.
- Frysz M, Gergei I, Scharnagl H, et al. Circulating sclerostin levels are positively related to coronary artery disease severity and related risk factors. J Bone Miner Res 2022;37(2):273-84. https://doi.org/10.1002/jbmr.4467
- Golledge J, Thanigaimani S. Role of sclerostin in cardiovascular disease. Arterioscler Thromb Vasc Biol 2022;42(7):e187-202. https://doi.org/10.1161/ATVBAHA.122.317635
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377(15):1417-27. https://doi.org/10.1056/NEJMoa1708322
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375(16):1532-43. https://doi.org/10.1056/NEJMoa1607948
- Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 2018;103(9):3183-93. https://doi.org/10.1210/jc.2017-02163
- Lim SY. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk. Womens Health (Lond) 2022;18:1-14. https://doi.org/10.1177/17455057221125577
- Baek KH, Chung YS, Koh JM, et al. Romosozumab in postmenopausal korean women with osteoporosis: A randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metab (Seoul) 2021;36(1):60-9. https://doi.org/10.3803/EnM.2020.848
- Amgen Inc. A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis. Clinicaltrials.gov; 2013 [Update Posted 2018 Nov 8]. Available from https://clinicaltrials.gov/ct2/show/NCT02016716. Accessed June 5, 2023.
- Ishibashi H, Crittenden DB, Miyauchi A, et al. Romosozumab increases bone mineral density in postmenopausal japanese women with osteoporosis: A phase 2 study. Bone 2017;103:209-15. https://doi.org/10.1016/j.bone.2017.07.005
- McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370(5):412-20. https://doi.org/10.1056/NEJMoa1305224
- Schemitsch EH, Miclau T, Karachalios T, et al. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am 2020;102(8):693-702. https://doi.org/10.2106/JBJS.19.00790
- Poutoglidou F, Samoladas E, Raikos N, et al. Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review. J Clin Densitom 2022;25(3):401-15. https://doi.org/10.1016/j.jocd.2021.11.005
- Singh S, Dutta S, Khasbage S, et al. A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int 2022;33(1):1-12. https://doi.org/10.1007/s00198-021-06095-y
- Lv F, Cai X, Yang W, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis. Bone 2020;130:115121.
- Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet 2017;390(10102):1585-94. https://doi.org/10.1016/S0140-6736(17)31613-6
- Rodriguez AJ, Ernst MT, Nybo M, et al. Oral bisphosphonate use reduces cardiovascular events in a cohort of danish patients referred for bone mineral density. J Clin Endocrinol Metab 2020;105(10):3215-25. https://doi.org/10.1210/clinem/dgaa481
- Sing CW, Wong AY, Kiel DP, et al. Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 2018;33(8):1422-34. https://doi.org/10.1002/jbmr.3448